arrow
A

Anna Spina

university of parma
H指数:15
被引数:703
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells

CXCR4、CXCR7和PBRM1是人类肾癌细胞中依维莫司和卡博赞尼耐药性的相关因素。

2026-03-280
OAAI
CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC
2026-01-010
PRE
Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial

高级别子宫内膜癌中的同源重组修复状态:来自随机、II期MITOEND 3试验的探索性生物标志物分析

2025-12-050
OAAI
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trial

肿瘤浸润性白细胞作为接受贝伐珠单抗治疗的卵巢癌患者的预后生物标志物:来自IV期MITO16A/MaNGO OV-2临床 trial 的结果

2025-11-170
OAAI
Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin plus paclitaxel/avelumab (MITO-END3 trial)

外周单核细胞源性抑制性细胞与单中心接受卡铂联合紫杉醇/阿维单抗治疗子宫内膜癌患者分子亚型的相关性(MITO-END3试验)

2025-04-170
OA
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial
2025-01-011
OAAI
The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells

CXCR4拮抗剂R54靶向人类卵巢癌细胞中的上皮-间质转化(EMT)。

2024-12-190
OA
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study

接受贝伐单抗联合一线化疗的卵巢癌患者的TP53突变和生存率: MITO16A/MaNGO OV-2研究的结果

2024-10-160
OAAI
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial
2024-07-010
PRE
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy
2024-07-014
PRE
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial
2023-04-112
OAAI
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
2022-10-0121
OAAI
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab
2022-08-312
OAAI
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)
2022-07-2212
OA
Immunotherapy in cervix cancer

子宫颈癌的免疫治疗

2020-11-0137
PREAI
Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience
CELLS
IF5.2
2020-04-0710
OAAI
NZ-GMP Approved Serum Improve hDPSC Osteogenic Commitment and Increase Angiogenic Factor Expression
2016-08-1920
OAAI
Intracellular signaling cascades triggered by the NK1 fragment of hepatocyte growth factor in human prostate epithelial cell line PNT1A
2011-12-0125
PREAI
Serotonin transporter gene deficiency is associated with sudden death of newborn mice through activation of TGF-β1 signalling
2009-11-0131
PREAI